KRAS and neoplasm: Mazieres et al., in a retrospective cohort, demonstrated that KRAS-driven tumors express higher rates of PD-L1 and present higher tumor mutational burden compared with other oncogenic alterations, suggesting that it might predict better responses to IT (2).